Key insights
- Piper Sandler maintained an Overweight rating on CVS Health with a $113 price target, citing potential upside and improved guidance. The firm's analysis suggests significant upside potential if current trends persist, driven by favorable prior year development and outperformance in government programs. This positive outlook, coupled with upward earnings revisions from other analysts and a fair value assessment, indicates a bullish sentiment for CVS Health stock.
Investing.com - Piper Sandler reiterated an Overweight rating on CVS Health stock (NYSE:CVS) with a price target of $113.00. The stock currently trades at $90.98, suggesting potential upside of around 13% based on the average analyst target.
The firm updated its model and maintained the price target based on an unchanged 12x multiple of calendar year 2028 adjusted earnings per share, previously calendar year 2027, due to the passage of time.
CVS Health raised its calendar year 2026 Health Care Benefits adjusted operating income guidance by $420.0 million to reflect net favorable prior year development as of the first quarter of 2026. The revised calendar year 2026 Health Care Benefits adjusted operating income guidance maintains all prior assumptions despite early evidence of fundamental outperformance across government programs. This optimism aligns with broader analyst sentiment, as InvestingPro data shows 15 analysts have revised their earnings upwards for the upcoming period. The platform also indicates CVS appears undervalued based on its Fair Value analysis.
Piper Sandler stated that if first quarter 2026 trends hold, Health Care Benefits medical loss ratio could come in 50-plus basis points better than guidance calling for 90.0% to 91.0%. The firm said this suggests at least $670.0 million of upside, or a 16.1% beat, versus the midpoint of revised calendar year 2026 Health Care Benefits adjusted operating income guidance.
The firm noted that if calendar year 2026 Health Care Benefits adjusted operating income upside does not materialize, it would be compelled to revisit its calendar year 2027 Medicare Advantage margin assumptions in consideration of decelerating rates and implied calendar year 2026 Medicare Advantage margin progress.For deeper insights into CVS’s financial health and growth prospects, investors can access the comprehensive Pro Research Report, available for this and 1,400+ other US equities on InvestingPro.
In other recent news, ARCTRUST Private Capital has acquired a seven-property retail portfolio, which includes locations for Pinnacle Bank, CVS Pharmacy, and NAPA Auto Parts across six states. This portfolio, offered as ARCTRUST Exchange II DST, encompasses approximately 51,192 net rentable square feet with a weighted average lease term of 13.6 years. In another development, CVS Health announced that CVS Caremark will expand its commercial formularies by adding Zepbound (tirzepatide) as a preferred option effective October 1, 2026. Additionally, CVS Health revealed the U.S. Bankruptcy Court approved the sale of Omnicare LLC to GenieRx Holdings LLC, a partnership between Milrose Capital LLC and Integro Asset Management LLC.
Meanwhile, Eli Lilly received a boost as CVS Caremark added its obesity medicine Zepbound to its preferred drug list, ensuring coverage by the nation’s largest pharmacy benefit managers. This move allows broader access to Lilly’s full obesity medicine portfolio by October 1. Furthermore, Bernstein SocGen Group raised its price target for CVS Health to $106, maintaining an Outperform rating, citing a potential 15% upside. These developments reflect significant strategic moves and analyst expectations for the companies involved.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy. Get the bottom line for CVS plus thousands of other stocks and find your next hidden gem with massive upside.